Treatments are not one-size fits all which begs the question : how do we know which treatment is the right one? Cancer experiments in London, England may have found the answer to this question.
Cancer researchers in Europe developed a blood test that could help target treatment for men with advanced prostate cancer :
“They found those with multiple copies of a particular gene did not respond to abiraterone and enzalutamide – drugs commonly used to treat advanced cases. These drugs are given to men whose cancer is no longer responding to traditional hormone therapy and has started to spread. Lead researcher Dr Gerhardt Attard, from the Centre for Evolution and Cancer at the Institute of Cancer Research in London, said: “Abiraterone and enzalutamide are excellent treatments for advanced prostate cancer and some men can take these drugs for years without seeing a return of their cancer. But in other men, these drugs do not work well and the disease rapidly returns.”
Moreover, there is currently no approved test to help doctors choose the best treatments for a patient but this extensive blood test, using your gene and blood make-up, which sees which men are likely to respond to abiraterone and enzalutamde, and which men need other treatment plans. With the help of pharmacogenetics, efficacy of treatments is viable!